Suppr超能文献

通过深思熟虑的抗菌药物敏感性测试和报告策略指导抗菌药物管理:2023 年的更新方法。

Guiding antimicrobial stewardship through thoughtful antimicrobial susceptibility testing and reporting strategies: an updated approach in 2023.

机构信息

Department of Pathology, University of Michigan Medical School , Ann Arbor, Michigan, USA.

Department of Medicine, Division of Allergy, Immunology and Infectious Diseases, Rutgers Robert Wood Johnson Medical School , New Brunswick, New Jersey, USA.

出版信息

J Clin Microbiol. 2023 Nov 21;61(11):e0007422. doi: 10.1128/jcm.00074-22. Epub 2023 Sep 28.

Abstract

Antimicrobial susceptibility test and report guidelines are an important tool for antimicrobial stewardship programs. Since 1972, Tables 1 within the Clinical and Laboratory Standards Institute (CLSI) M100 document have provided a general framework upon which clinical microbiologists and antimicrobial stewardship teams can build algorithms for susceptibility testing and reporting that meet the specific needs of their institution. Many changes were made to Tables 1 in M100-Ed33 to modernize the content to reflect the landscape of current clinical practice, including the growing armamentarium of antimicrobial agents, the emergence of new mechanisms of antimicrobial resistance, the increasing prevalence of infections caused by multidrug-resistant organisms, and updated consensus recommendations for first-choice and alternative agents for treatment. With these items in mind, the CLSI Table 1 working group revised Tables 1 with the ultimate goal of supporting institutions in the creation of individualized test and report strategies that support local antimicrobial stewardship program initiatives. These strategies are built on the concepts of selective and cascade reporting. This minireview introduces the concept of CLSI M100-Ed33 Tables 1, describes the changes to Tables 1 introduced in 2023, and provides clinical vignettes that demonstrate how Tables 1 can be used in various scenarios to devise antimicrobial susceptibility test and report strategies.

摘要

抗菌药物敏感性试验和报告指南是抗菌药物管理计划的重要工具。自 1972 年以来,临床和实验室标准协会(CLSI)M100 文件中的表 1 为临床微生物学家和抗菌药物管理团队提供了一个通用框架,可以在此基础上构建满足其机构具体需求的药敏试验和报告算法。为了使内容现代化,以反映当前临床实践的情况,包括抗菌药物武器库的不断扩大、新的抗菌药物耐药机制的出现、多药耐药生物体引起的感染的流行率不断增加,以及更新的首选和替代治疗药物的共识建议,M100-Ed33 版对表 1 进行了许多修改。考虑到这些因素,CLSI 表 1 工作组对表 1 进行了修订,最终目标是支持各机构制定个体化的试验和报告策略,以支持当地的抗菌药物管理计划举措。这些策略建立在选择性和级联报告的概念之上。本文简要介绍了 CLSI M100-Ed33 表 1 的概念,描述了 2023 年引入的表 1 的变化,并提供了临床病例,展示了如何在各种情况下使用表 1 来设计抗菌药物敏感性试验和报告策略。

相似文献

2
Role of the Clinical Microbiology Laboratory in Antimicrobial Stewardship.临床微生物学实验室在抗菌药物管理中的作用。
Med Clin North Am. 2018 Sep;102(5):883-898. doi: 10.1016/j.mcna.2018.05.003. Epub 2018 Jul 14.
4
Introducing the new face of CLSI M100 in 2023: An explanatory review.2023 年推出的 CLSI M100 新版本:解说性评论。
Indian J Med Microbiol. 2023 Nov-Dec;46:100432. doi: 10.1016/j.ijmmb.2023.100432. Epub 2023 Aug 8.

引用本文的文献

7
Antimicrobial resistance: Current challenges and future directions.抗菌药物耐药性:当前挑战与未来方向。
Med J Armed Forces India. 2025 May-Jun;81(3):247-258. doi: 10.1016/j.mjafi.2024.07.006. Epub 2024 Sep 19.

本文引用的文献

6
Nudging In MicroBiology Laboratory Evaluation (NIMBLE): A scoping review.推动微生物学实验室评估(NIMBLE):范围综述。
Infect Control Hosp Epidemiol. 2019 Dec;40(12):1400-1406. doi: 10.1017/ice.2019.293. Epub 2019 Nov 4.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验